MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Masimo raises outlook on Street-beating Q1 numbers

Masimo raises outlook on Street-beating Q1 numbers

By

MasimoMasimo (NSDQ:MASI) yesterday raised its outlook for the rest of the year after posting first-quarter results that beat both sales and earnings forecasts, despite lower profits.

Irvine, Calif.-based Masimo reported profits of $45.6 million, or 82¢ per share, on sales of $213.0 million for the three months ended March 31, for a bottom-line slide of -11.5% on sales growth of 8.3% compared with Q1 2017.

Adjusted to exclude one-time items, earnings per share were 75¢, 6¢ ahead of the consensus forecast on Wall Street, where analysts were looking for revenues of $205.8 million.

“We had another record quarter for product revenues and earnings, demonstrating once again the clinical and economic value of our innovative technologies for improving patient care. We achieved another strong quarter of shipments of our noninvasive monitoring technologies, at 53,600. Our positive outlook is visible in our higher guidance for sales and earnings in 2018 as we introduce important new products and gain new customers around the world,” founder, chairman & CEO Joe Kiani said in prepared remarks.

Masimo said it now expects to report adjusted EPS of $2.88, up from prior guidance for $2.80, on sales of $846 million, compared with $836 million previously.

MASI shares were up 1.4% to $93.00 apiece today in mid-day trading.

In case you missed it

RSS From Medical Design & Outsourcing

  • Employees say Intuitive, Boston Scientific, J&J, Medtronic are among the best places to work in 2022
    Intuitive Surgical, Boston Scientific, Johnson & Johnson and Medtronic were recently named by Glassdoor as Best Places to Work in 2022 based on employee reviews. Each year, Glassdoor uses feedback that employees have shared on the website over the past 12 months to compile a list of the best places to work for the upcoming… […]
  • Medtronic’s M&A strategy explained by CFO Karen Parkhill
    When Medtronic CFO and EVP Karen Parkhill looks back at the medical device manufacturer’s performance through the COVID-19 pandemic, she recalls a key decision that rankled investors but paid off in the long run. “When I first joined Medtronic, it was shortly after the Covidien merger and we had taken on a lot of debt… […]
  • Loftware acquires Prisym ID
    Loftware announced that it acquired Prisym ID, a provider of regulated content and label management solutions. Prisym ID focuses on clinical trials, medical device and pharmaceutical labeling, with the acquisition set to expand Loftware’s enterprise labeling solution offerings for the medical device and pharmaceutical industries while enhancing Loftware’s end-to-end, cloud-based labeling platform with advanced clinical… […]
  • BD, Pfizer, Wellcome want to improve hospitals’ antimicrobial practices
    BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices. The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps… […]
  • iRhythm CEO considers costs on the path to profitability
    Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind. iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it… […]
  • Integer Holdings makes additions to its executive team
    Integer Holdings today announced that it has appointed three new executives to its leadership team. The appointments come as part of a planned transition due to retirements. Margaret Cathy is being promoted to senior VP of quality and regulatory affairs; Andrew Senn is being promoted to senior VP of strategy and business development and McAlister… […]
  • Healthcare venture funding boomed in 2021; expect a slowdown in 2022
    An all-time-high $86 billion of venture capital investments in the U.S. and Europe last year bested 2020’s record haul by more than 30% and grew more than 150% from 2019, according to a new analysis by Silicon Valley Bank. After record-setting quarters in the first half, however, VC investment slowed due to poor performing biopharma… […]
  • Medical technical writers vs. medical writers: What’s the difference?
    By CfPIE Pharmaceutical organizations often have trouble conveying complex medical concepts to “layman” users like patients and the public. Being able to communicate medical device usage instructions, clinical trial results, patient education materials, and other important materials is essential for end-users to get the most out of your products and services while preventing potential health… […]
  • Traco Power touts new encapsulated AC/DC power supplies
    Traco Power this week announced it launched its new TPP 40E and TPP 65E miniature encapsulated AC/DC power supplies. The new AC/DC power supplies have safety approvals for both medical and industrial applications. Each wattage family has six models, offering single outputs of 5, 12, 15, 24, 36, 48V with up to 94% efficiency, according… […]
  • Johnson & Johnson and Microsoft partner up on digital surgery
    Johnson & Johnson said today it will use Microsoft’s cloud computing services to better connect surgeons and patients in a digital surgery ecosystem. New Brunswick, New Jersey–based Johnson & Johnson (NYSE: JNJ) selected Redmond, Washington-based Microsoft (NASDAQ: MSFT) as the preferred cloud provider for JNJ’s digital surgery solutions and to build out its digital surgery… […]
  • Hugo, renal denervation and diabetes businesses to drive growth despite setbacks, Medtronic CEO says
    Although three major pipelines at Medtronic (NYSE:MDT) have hit recent speed bumps, CEO Geoff Martha reiterated his belief that they will be major growth factors. In October, the medtech giant announced that the clinical study of its Symplicity Spyral renal denervation (RDN) system for hypertension would continue into next year after lacking the positive results needed to end enrollment… […]